Progress in the field of obesity may seem to have progressed at a snail's pace, but
tremendous advances have been made during the last few decades in our understanding of …

Cardiovascular disease (CVD) is a leading global cause of death, with preventable risk
factors like obesity contributing most to it. Obesity's association with CVD originate from …

The recently reported SELECT trial (Semaglutide Effects on Heart Disease and Stroke in
Patients With Overweight or Obesity) 3 tested this hypothesis using the higher-dose …

As emphasized in our previous “From the Editors” commentary 1 and the accompanying
editorial 2 and joint response from the National Lipid Association and the American Society …

Cardiovascular disease (CVD) is a major cause of morbidity and mortality. Although it has
been widely appreciated that obesity is a major risk factor for CVD, treatments that produce …

The importance of the obesity-lipid connection has suffered from the traditional reductionism
view of science. Excess body weight has rarely been deemed an independent risk factor for …

Overweight or obesity has been independently associated with increased cardiovascular
risk, yet interventional trials of lifestyle or pharmacologic management strategies for …

Objective This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

More than half the world population is expected to be overweight or obese by the year 2035
[1]. Obesity and atherosclerotic cardiovascular disease have always been a fatal …

• In the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or
Obesity trial, the SELECT Investigators tested the hypothesis that the addition of …